Published in Oncotarget on August 14, 2015
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res (2005) 30.44
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Cancer genome landscapes. Science (2013) 25.33
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med (2007) 10.47
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst (1996) 4.91
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol (2014) 4.54
Genomics and drug response. N Engl J Med (2011) 4.35
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26
Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol (2006) 2.37
Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res (2008) 2.31
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res (2002) 1.96
The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res (2001) 1.90
Melanoma survival disadvantage in young, non-Hispanic white males compared with females. JAMA Dermatol (2013) 1.78
Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev (2010) 1.74
Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med (2012) 1.67
East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer (2011) 1.66
Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res (2012) 1.63
Gender differences in stage-adjusted bladder cancer survival. Urology (2000) 1.55
Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett (2011) 1.48
Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res (2009) 1.43
Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol (2010) 1.42
Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res (2007) 1.38
Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995-2004. Am J Epidemiol (2007) 1.36
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
Lung cancer in Asian women-the environment and genes. Respirology (2005) 1.25
Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol (2011) 1.21
A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci Signal (2011) 1.20
Integrated analyses of copy number variations and gene expression in lung adenocarcinoma. PLoS One (2011) 1.19
Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One (2011) 1.18
Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer (2007) 1.14
A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res (2014) 1.12
A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS One (2013) 1.08
Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer (1995) 1.06
Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS One (2013) 1.05
Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci U S A (1998) 0.99
Racial, ethnic, and gender variations in cancer risk: considerations for future epidemiologic research. Environ Health Perspect (1995) 0.98
An integrative characterization of recurrent molecular aberrations in glioblastoma genomes. Nucleic Acids Res (2013) 0.96
Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer Lett (2011) 0.94
East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer (2011) 0.92
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology (2013) 0.91
The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. Curr Drug Metab (2007) 0.90
Deciphering causal and statistical relations of molecular aberrations and gene expressions in NCI-60 cell lines. BMC Syst Biol (2011) 0.84
Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. Hepatology (2019) 2.03
Radiogenomics: radiobiology enters the era of big data and team science. Int J Radiat Oncol Biol Phys (2014) 1.10
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res (2014) 0.91
Down-regulation of NDRG1 promotes migration of cancer cells during reoxygenation. PLoS One (2011) 0.81
Genome-wide gene expression analysis implicates the immune response and lymphangiogenesis in the pathogenesis of fetal chylothorax. PLoS One (2012) 0.76
Mitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells. Oncotarget (2016) 0.75
Long range personalized cancer treatment strategies incorporating evolutionary dynamics. Biol Direct (2016) 0.75
Exploring candidate biological functions by Boolean Function Networks for Saccharomyces cerevisiae. PLoS One (2017) 0.75